Annual Report for the Financial Year 2025-26

September 03, 2026 BSE Limited National Stock Exchange of India Ltd., Department of Corporate Relationship Department of Corporate Services 1st Floor, New Trade Ring, Rotunda Building Exchange Plaza, 5th Floor, Phiroze Jeejeebhoy Towers C-1, Block G,Bandra Kurla Complex, Dalal Street, Mumbai- 400001 Bandra (E),Mumbai – 400 051 Scrip Code: 524742 S c r i p C o d e : C A P L I P O I N T . Dear Sir/Madam, Sub: Annual Report for the Financial Year 2025-26 – Regulation 34 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) The 35th Annual General Meeting (“AGM”) of the Company is scheduled to be held on Friday, September 25, 2026, at 10.00 A.M (IST) through Video Conferencing / Other Audio-Visual Means (“VC/OAVM”), in accordance with the relevant circulars issued by Ministry of Corporate Affairs (“MCA”) and Securities and Exchange Board of India (“SEBI”). Pursuant to Regulation 34(1) of SEBI Listing Regulations, we are submitting herewith the Annual Report along with the Notice of the 35th AGM which has been sent to members through electronic mode. For those members whose email addresses are not registered with the Registrar and Share Transfer Agent (“RTA”)/ Depositories, a letter containing the web link for accessing the Annual Report and Notice is being sent. The Annual Report along with Notice convening the 35th AGM has also been uploaded on the Company’s website at https://www.caplinpoint.net/index.php/annual-report/ This is for your kind information and records. Thanking You, Sincerely yours, For Caplin Point Laboratories Limited Venkatram G General Counsel & Company Secretary Membership No A23989 Encl: A/a Caplin Point Laboratories Limited Annual Report 2025-26 Compounding Without Compromise Caplin Point Laboratories Limited Annual Report 2025-26 COMPOUNDING WITHOUT COMPROMISE 2 | Annual Report 2025-26 CORPORATE OVERVIEW MANAGEMENT REPORTS STANDALONE FINANCIAL STATEMENTS CONSOLIDATED FINANCIAL STATEMENTS NOTICE Fifteen years. One direction. Caplin’s FY26 numbers, revenue of 2,187 Crores with 12.89% growth, net profit 650 Crores, up by 20.08% Y-o-Y, are not an aberration. But the latest entry in a decade-long pattern: profit has compounded at roughly 27%* over the past decade, without a single year of debt funding the climb. This foundational rigour now propels us into more sophisticated territories. Caplin Steriles USA turned profitable within its first year. Backward integration, Blow-Fill-Seal technology and pre-filled syringes are reshaping the product mix toward complexity. Our core business of LatAm received a fresh impetus in the form of land acquisition in Mexico for setting up our first facility in that region along with a proposed state-of-the-art liquid oral facility in Guatemala. None of it requires leverage, dilution, or a pause in cash generation, with free cash reserves standing at ₹1,471 Crores, 21X** growth over the past decade. For us, expansion does not translate to a compromise on stability. Instead, we continue to demonstrate that ambitious scale and fiscal discipline are twin forces that compound together, year after year. * Net Profit CAGR between FY16 (₹58 Crores) and FY26 (₹650 Crores) ** Cash Reserves (Free Cash Reserves) ₹68 Crores in FY16 to ₹1,471 Crores in FY26 Annual Report 2025-26 | 1 COMPOUNDING NUMBERS, WITHOUT COMPROMISE Net Worth (` Crore) Profit After Tax (` Crore) 4,000.00 3,630.80 700 649.73 3,500.00 600 541.09 2,886.39 3,000.00 500 461.42 2,346.83 2,500.00 376.99 1,907.27 400 2,000.00 308.45 1,509.88 1,500.00 1,000.00 500.00 100 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 Market Cap (` Crore) Total Income (` Crore) 16,000.00 2,500.00 2,302.73 14,000.00 13,461.00 2,033.90 11,438.24 2,000.00 1,761.04 12,000.00 10,000.00 1,522.71 10,000.00 1,500.00 1,308.16 8,000.00 1,000.00 6,000.00 5,135.00 4,529.00 4,000.00 500.00 2,000.00 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 2 | Annual Report 2025-26 CORPORATE OVERVIEW MANAGEMENT REPORTS STANDALONE FINANCIAL STATEMENTS CONSOLIDATED FINANCIAL STATEMENTS NOTICE THE PASSION FOR COMPOUNDING NUMBERS TOTAL REVENUE 22.1% 10 Years CAGR OPERATING REVENUE 313 Cr to 2,303 Cr 21.6% 2015-16 to 2025-26 (` Cr.) 10 Years CAGR 16.2% 310 Cr to 2,187 Cr 5 Years CAGR 2015-16 to 2025-26 (` Cr.) 1,085 Cr to 2,303 Cr 15.6% 2020-21 to 2025-26 (` Cr.) 5 Years CAGR 1,061 Cr to 2,187 Cr EBITDA 2020-21 to 2025-26 (` Cr.) 26.0% 10 Years CAGR 87 Cr to 876 Cr PAT 2015-16 to 2025-26 (` Cr.) 27.3% 20.0% 10 Years CAGR 5 Years CAGR 58 Cr to 650 Cr 352 Cr to 876 Cr 2015-16 to 2025-26 (` Cr.) 2020-21 to 2025-26 (` Cr.) 21.0% 5 Years CAGR 251 Cr to 650 Cr 2020-21 to 2025-26 (` Cr.) FREE CASH RESERVES 68 Cr to 1,471 Cr 2015-16 to 2025-26 (` Cr.) 470 Cr to 1,471 Cr 26.5% 2020-21 to 2025-26 (` Cr.) 10 Years CAGR 77 Cr to 803 Cr 2015-16 to 2025-26 (` Cr.) 20.7% 5 Years CAGR 314 Cr to 803 Cr 2020-21 to 2025-26 (` Cr.) Annual Report 2025-26 | 3 ANOTHER YEAR OF YEAR-ON-YEAR COMPOUNDING Operating Revenue FY26 EBITDA FY26 ₹2187.19 Crores ₹876.39 Crores 12.89% Y-o-Y Growth 17.90% Y-o-Y Growth Net Profit FY26 PBT FY26 ₹649.73 Crores ₹802.79 Crores 20.08% Y-o-Y Growth 18.62% Y-o-Y Growth EPS FY26 Gross R&D `84.36 Investment FY26 19.54% Y-o-Y ₹101 Crores Growth 13.50% Y-o-Y Growth 4 | Annual Report 2025-26 CORPORATE OVERVIEW MANAGEMENT REPORTS STANDALONE FINANCIAL STATEMENTS CONSOLIDATED FINANCIAL STATEMENTS NOTICE Annual Report 2025-26 | 5 COMPOUNDING OPERATIONS, WITHOUT COMPROMISE OPERATIONAL HIGHLIGHTS: New Therapeutic Areas Entered  GLP-1 (weight management and diabetes) with filings  Oncology Injectables nearing commercialization  Biosimilars and Peptides under development  API Manufacturing with complete R&D scale and refurbished plant New Product Launches  29 US Injectable Products - CSL USA  3 Ophthalmic Products – CSL USA Multiple USFDA Approvals (2025-2026):  Acetaminophen Injection, Infusion Bags  Linezolid  Nicardipine Hydrochloride  Milrinone Lactate  Haloperidol Decanoate Injection  Phytonadione Injectable Emulsion  Desmopressin Acetate Injection Country-specific Approvals and Certificates  25 Product Approvals in Mexico  10 ANDA Approvals in US and Regulated Markets  15 ANDA acquired from Third Party for US and Regulated Markets  EU GMP Renewal Certificate  Invima approval for Puducherry Injectables site Ongoing Capacity Additions  In-house API Unit to cater to 60% of our products  Oral Solid Dosage facility for regulated markets in Puducherry  Kakkalur Oncology Injectable Section  Oncology unit in Thervoy Kandigai  3X expansion of IV Bag lines 6 | Annual Report 2025-26 CORPORATE OVERVIEW MANAGEMENT REPORTS STANDALONE FINANCIAL STATEMENTS CONSOLIDATED FINANCIAL STATEMENTS NOTICE Annual Report 2025-26 | 7 COMPOUNDING FOR CIRCULAR ECONOMY NON-FINANCIAL HIGHLIGHTS Environment Social Governance  1,15,10,433 KWh Renewable power  2,249 employees in India, 512 overseas  2 out of 5 Independent Directors used amounting to 36.65% of power employees in Subsidiaries and 628 exercise active oversight in Subsidiary consumed by the group. contract employees. (As of 31st March, Boards  52.39% water recycled and reused in 2026)  Significant and stable Promoter FY26  33.13% women representation in Indian participation in risk capital workforce, 46% women representation  374.07 MT Waste generated  Zero Unfavorable observations in any in global workforce and 62% women  Out of 315.71 MT Waste disposition, representation in contract workforce. of the last three audits conducted by 17.69% was disposed through  100% of permanent employees — both USFDA incineration, 18.93% to Alternate Fuel male and female — are covered by Health  Operations compliant with multi- Recovery Facility and 14.39% recycled Insurance and Accident Insurance. jurisdiction regulatory requirements  1 key manufacturing unit with Zero  14,300 hospitals, pharmacies, clinics, like USFDA, INVIMA, COFEPRIS etc Liquid Discharge etc. in the US. 30,000+ t [Showing first 8,000 characters — download PDF for full document]